Published in final edited form as:

Int J STD AIDS. 2015 December ; 26(14): 1040–1048. doi:10.1177/0956462415570159.

Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles

Ronald A Brooks¹, Raphael J Landovitz², Rotrease Regan¹, Sung-Jae Lee³, and Vincent C Allen Jr⁴

¹Department of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

²Associate Professor of Medicine, Division of Infectious Diseases, Center for Clinical AIDS Research & Education, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

³Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

⁴Department of Psychology, University of California, Los Angeles, CA, USA

Abstract

This study assessed perceptions of Pre-Exposure Prophylaxis (PrEP) and their association with PrEP adoption intention among a convenience sample of 224 low socioeconomic status black men who have sex with men (BMSM) residing in Los Angeles. Participants received educational information about PrEP and completed an in-person interview. More than half (60%) of participants indicated a high intention to adopt PrEP. Younger BMSM (18-29 years) were twice as likely to report a high intention to adopt PrEP compared to older BMSM (30+ years). Only 33% of participants were aware of PrEP and no participant had ever used PrEP. Negative perceptions were associated with a lower PrEP adoption intention and included being uncomfortable taking an HIV medicine when HIV-negative and not knowing if there are long-term side effects of taking an HIV medication. These findings suggest that BMSM may adopt PrEP but that negative perceptions may limit its uptake among this population. In order to facilitate PrEP adoption among BMSM targeted educational and community awareness programs are needed to provide accurate information on the benefits of PrEP and to address the negative perceptions of PrEP held by local BMSM populations.

Keywords

African-American; men who have sex with men; gay; bisexual; pre-exposure prophylaxis; biomedical; HIV prevention

Introduction

In the United States, black men who have sex with men (BMSM) have been disproportionately impacted by the HIV/AIDS epidemic. In 2011, BMSM had an estimated 11,805 incident HIV infections, which represented the largest percentage (39%) of new infections among MSM of all races and ethnicities.[1] Young BMSM ages 13 to 24 are especially burdened by HIV. In 2010, young BMSM had an estimated 4,800 incident HIV infections, more than twice as many as young white or Latino/Hispanic MSM.[2] In addition, young BMSM comprised the largest percentage (45%) of new HIV diagnoses among BMSM, placing them at greater risk of HIV infection relative to older BMSM (35 years).[2] Additional prevention strategies are urgently needed to help curb the spread of HIV in this heavily-impacted population.

For most of the HIV/AIDS epidemic manualized evidence-based behavioral interventions have been utilized with high-risk groups for HIV prevention.[3] Most of these interventions focus on some form of behavioral risk reduction (e.g., increasing condom use, reducing number of sex partners, decreasing substance use in the context of sexual behaviors). Unfortunately, only a very limited number of these interventions were developed or adapted specifically for BMSM.[4]. While behavioral interventions remain an important part of our HIV prevention efforts, in recent years biomedical strategies have moved to the forefront of HIV prevention activities, providing innovative technologies to help curb the spread of HIV infection. Multiple biomedical strategies such as Pre-Exposure Prophylaxis (PrEP), Treatment as Prevention, and medical male circumcision have all shown efficacy in reducing HIV acquisition.[5-10] Other strategies such as intermittent PrEP, microbicides, and HIV vaccines have shown promise or are currently being tested.[11-15] Overall, biomedical strategies have raised hopes for much more effective HIV prevention efforts.

PrEP is a biomedical intervention that can help reduce new HIV infections. PrEP has been proven efficacious in preventing HIV infection in multiple high-risk populations with daily use of the HIV antiretroviral medication Truvada®. [5-7] The U.S. Food and Drug Administration (FDA) has approved Truvada (a combination of 300 mg of tenofovir and 200 mg of emtricitabine) for use as PrEP,[16] and the U.S. Centers for Disease Control and Prevention (CDC) has released clinical guidelines for administering PrEP to high-risk populations.[17] At present, demonstration projects are underway to assess the safety, acceptability, and feasibility of implementing PrEP with high-risk populations in “real-world” settings.[18] Despite these advances, important challenges remain in fully implementing PrEP, especially among high-risk BMSM.

A host of social issues may influence PrEP adoption among Black MSM. For example, the stigma attached to HIV and homosexuality in the black community [19,20] may lead to greater trepidation about PrEP adoption for fear of mistakenly being identified as someone who is HIV positive due to the use of an HIV medication, or being identified as someone engaging in stigmatized behaviors (i.e., male-to-male sex). In addition, mistrust of the research community among blacks founded in part on the history of discrimination in the Tuskegee syphilis study [21,22] and beliefs in conspiracy theories surrounding the origin of HIV and the role of government in the AIDS epidemic may present significant challenges to

adoption of any type of biomedical prevention strategy by BMSM.[23,24] In addition, limited access to health care services, which is the source for delivery of PrEP, may also reduce the ability of BMSM to use PrEP.

While prior research suggests that, in general, MSM will use PrEP,[25-28] limited information exists on the attitudes and beliefs about PrEP and intentions to adopt PrEP among BMSM, which may impact its scalability and effectiveness in reducing HIV infections in this population.[29] In order to achieve a significant reduction in HIV infections, modelling studies indicate that wide coverage of PrEP is necessary among high-risk populations.[30,13] The present study examined perceptions of PrEP (i.e. PrEP-related attitudes and beliefs) and their association with PrEP adoption intentions among BMSM. These data provide an understanding of the perceptions of and intentions to adopt PrEP among BMSM, which may help inform PrEP implementation programs targeted to this population.

Methods

Between March 2012 and February 2013, 428 individuals were screened for the study. They had learned about the study from a variety of referral sources: friends (n=133); weekly internet postings on Craigslist.org (n=100); study flyer (n=92); text messages from a community-based organization serving BMSM (n=46); referred by a house father from the house and ball community (n=27); community presentations (n=16); and other sources (n=14). From those persons screened, 289 individuals were eligible and 224 completed the in-person study interview. Among those eligible, the lack of completion was primarily due to scheduling conflicts.

Participants were eligible to participate in the study if they were 18 years of age or older, identified as African-American/Black, HIV-negative by self-report, have had sex with a male partner in the previous six months, and resided in Los Angeles County. Equal numbers of younger (18-29 years of age) and older (30+ years of age) BMSM were recruited in order to ensure representation of younger BMSM in the study. All study materials were approved by the Institutional Review Board of the University of California, Los Angeles. Participants provided informed consent and received \$35 compensation for their participation.

Prior to the start of the interview each participant was given a one page information sheet about PrEP that included dosing instructions (i.e. taken once daily), level of effectiveness (i.e. 90% effective in preventing HIV infection if taken every day), and possible side effects (i.e. nausea, headache and unintentional weight loss) based on the iPrEx study results.[6] The interviewer then read the information sheet to the participant. Participants were also informed about the completion of the iPrEx study to establish for them that PrEP had been proven efficacious in a large clinical trial done with MSM. In addition, participants were told that PrEP does not protect against other sexually transmitted infections. At the end of the information session participants were asked if they understood the information provided, and any questions were answered before the start of the interview.

Measures

The outcome of interest was PrEP adoption intention. Participants rated the likelihood of using a PrEP medication that was 90% effective in preventing HIV infection using a 7-Point Likert-type scale: 1 (extremely unlikely) to 7 (extremely likely). The iPrEx study demonstrated that 90% efficacy can be achieved with high levels of adherence.[32] Prior to analyses the adoption intention data were recoded into a dichotomous variable: (1) “high adoption intention” if a participant reported being “very likely” or “extremely likely” to use PrEP; and (2) “low adoption intention” if a participant reported being “somewhat likely,” “not sure,” “somewhat unlikely,” “very unlikely,” or “extremely unlikely” to use PrEP. This conversion provided a more conservative estimate of PrEP adoption intention given that the study was measuring behavioral intention which is not a perfect predictor of actual future behavior.[33]

Information was collected on participants’ demographic characteristics, sexual behaviors in the previous six months, most recent sexual encounter, and perceptions of PrEP. Sexual behavior items were adapted from the CDC’s National Behavioral Surveillance Survey for MSM.[34] Condom use was measured as “all of the time,” “most of the time,” “occasionally,” “rarely,” or “never” and then dichotomized with “all of the time” signifying consistent condom use and the remaining responses indicating inconsistent condom use. Participants were asked about their agreement with 24 PrEP-related attitude and belief items (perceptions of PrEP) that were derived from earlier formative work.[25,35] Refer to Appendix 1 for a complete list of these items. At the end of the interview participants were asked about their awareness of and use of PrEP and non-occupational Post-Exposure Prophylaxis (PEP) prior to completing the study interview.

Statistical analyses

Statistical analyses were conducted using IBM SPSS Statistics version 21. Chi-square tests were used to assess bivariate associations between PrEP adoption intention and demographic characteristics, sexual risk behaviors, PrEP-related attitude and belief items, and PrEP and PEP knowledge and use. Multivariate logistic regression was used to identify correlates of PrEP adoption intention using variables significant in the bivariate analyses or theoretically considered important in predicting PrEP adoption intention among BMSM. For all analyses, the standard alpha level of 0.05 was considered to be statistically significant.

Results

Demographic characteristics by PrEP adoption intention

Demographic characteristics, distributed by PrEP adoption intention, are presented in Table 1. Participants ranged in ages from 18 to 65 years ($M = 33.5$, $SD = 11.8$) and were equally divided between younger (18-29 years) and older (30+ years) participants. The overwhelming majority (96%) of men identified as gay or bisexual. Participants were primarily lower socioeconomic status (SES), with 67% having very low incomes, 51% not working, and 46% with only a high school education or less. In total, 93% of participants reported two or more low SES factors. In the bivariate analysis, demographic characteristics were not statistically associated with PrEP adoption intention.

Sexual risk behavior by PrEP adoption intention

A significant proportion of participants reported high-risk sexual behaviors in the previous 6 months (see Table 1). About half (49%) reported having had 3 or more male sex partners. Over half (53%) reported engaging in receptive anal intercourse (RAI), with almost half (48%) of these participants reporting inconsistent condom use, and approximately one-third (37%) reporting no condom use during their most recent RAI encounter. In addition, an overwhelming majority (84%) reported engaging in insertive anal intercourse (IAI), with more than half (53%) of these participants reporting inconsistent condom use, and over one-third (38%) reporting no condom use during their most recent IAI event. In the bivariate analysis, there was no relationship between sexual risk behavior and PrEP adoption intention.

PrEP-related attitudes and beliefs by PrEP adoption intention

Nine of the original 24 PrEP-related attitude and belief items were significantly associated with PrEP adoption intention in the bivariate analysis (see Table 2). These items reflected both negative and positive perceptions of PrEP. Four statements were associated with a high intention to adopt PrEP: “I would be one of the first people to use PrEP if it were available” ($p<.001$); “If I was taking PrEP, I would feel more comfortable about having sex with someone who is HIV-positive” ($p=.04$); “If I was taking PrEP, I wouldn’t worry about becoming infected with HIV when having sex with someone who is HIV-positive” ($p=.003$); and “Taking a daily HIV medicine would be a good way to protect myself from getting HIV” ($p<.001$). Five statements were associated with a low intention to adopt PrEP: “I would be very uncomfortable taking HIV medicines when I don’t have HIV” ($p<.001$); “Not knowing if there are long-term side effects of taking a daily HIV medicine makes me very uncomfortable” ($p=.002$); “I would wait until other people were taking PrEP before I use it myself” ($p<.001$); “I would be very uncomfortable asking my doctor for PrEP pills to protect myself from getting HIV” ($p=.01$); and “I would be concerned that people will think I have HIV if I am taking an HIV medicine” ($p=.023$).

PrEP and PEP awareness and prior use by PrEP adoption intention

Participants had limited awareness of or prior use of both PrEP and PEP (see Table 3). About one-third (33.0% and 36.2%, respectively) had heard of PrEP and PEP. None of the participants had ever used PrEP but seven reported prior use of PEP. In the bivariate analysis, PrEP and PEP awareness and prior use were not statistically associated with PrEP adoption intention.

Multivariate logistic regression analysis

Included in the multivariate logistic regression model were PrEP-related attitude and belief variables significant in the bivariate analysis and demographic variables theoretically thought to contribute to PrEP adoption intention among BMSM (age, sexual identity, education). The model was developed to identify variables independently associated with PrEP adoption intention, while controlling for all other variables. In the final model, negative perceptions were independent predictors of a low PrEP adoption intention. Participants agreeing with the statements: “I would be very uncomfortable taking HIV

medicine when I don't have HIV" (AOR = 0.39, 95% CI = 0.16 - 0.91) and "Not knowing if there are long-term side effects of taking a daily HIV medicine makes me very uncomfortable" (AOR = 0.36, 95% CI = 0.14 - 0.88) were less likely to indicate a high PrEP adoption intention compared with participants who disagreed with these statements (see Table 4). In contrast, positive views were independent predictors of a high PrEP adoption intention. Participants agreeing with the statements: "I would be one of the first people to use PrEP if it were available" (AOR = 4.13, 95% CI = 1.74-9.81) and "Taking a daily HIV medicine would be a good way to protect myself from getting HIV" (AOR = 2.26, 95% CI = 1.6-3.17) were more likely to indicate a high PrEP adoption intention compared with participants who disagreed with these statements. Age was the only demographic predictor of future PrEP use. Younger participants (18-29) were two times more likely than older participants (30+) to indicate a high intention to adopt PrEP (AOR = 2.29, 95% CI = 1.06-4.93).

Discussion

These findings suggest that BMSM are likely to adopt a highly effective (90%) PrEP medication and that younger BMSM (18-29 years) are more likely to adopt PrEP compared to older BMSM (30+ years). Because young BMSM are disproportionately impacted by HIV infection it was encouraging to find that young BMSM will consider using PrEP. The uptake of PrEP among young BMSM has the potential to have a significant impact in reducing new HIV infections among BMSM. A feature that may also impact PrEP adoption among BMSM is their understanding of its level of effectiveness. The iPrEx study demonstrated that higher efficacy (90%) is attainable with high levels of adherence.[32] As PrEP continues to roll out, a challenge remains for community groups, public health departments, and medical providers to accurately present and interpret PrEP efficacy data from clinical trials to BMSM, and to emphasize that the efficacy of PrEP is dependent on adherence.[36]

In the present study, we found that BMSM had limited knowledge and use of PrEP and PEP. Only one-third of participants had any prior knowledge of PrEP. This finding is consistent with what has been observed in multiple studies of multi-racial/ethnic MSM populations. [27, 37-39] Similarly, only about one-third of participants had any prior knowledge of PEP. This finding is also consistent with what has been reported for a multi-racial/ethnic sample of MSM.[27] None of the study participants had ever used PrEP but seven men reported prior use of PEP. Limited awareness and use of PrEP was expected given that PrEP is a new intervention and at the time of this study was not available in the community. The limited awareness of PEP was unexpected. In Los Angeles PEP has been available at no-cost since 2009, offered by the public health department in two community-clinic settings, with one of the clinics located in a predominantly African-American community. Even with its availability in the community, BMSM had limited knowledge of this biomedical prevention option. The limited knowledge of PrEP and PEP suggests that greater efforts are needed to raise community awareness and disseminate information specifically to BMSM about biomedical interventions and their availability in the community. This should include increasing BMSM and provider awareness of existing PrEP medication assistance programs

and the ability to access PrEP through private health insurance and publicly funded insurance programs (e.g., Medicaid).

The perceptions BMSM have regarding using PrEP may impact its scalability with this population. These results demonstrate that negative perceptions are associated with a low intention to use PrEP and positive perceptions are associated with a high PrEP adoption intention. Predictors of a low PrEP adoption intention included statements reflecting the apprehension BMSM may have about taking a prescription medication for an illness they do not have (“I would be very uncomfortable taking HIV medicines when I don’t have HIV”) and concerns about long-term side effects (“Not knowing if there are long-term side effects of taking a daily HIV medicine makes me very uncomfortable”). This finding is consistent with what has been observed in other studies with multi-racial/ethnic MSM populations. [25,26,29,40] Positive predictors of a high intention to adopt PrEP included statements reflecting participants’ enthusiasm for PrEP (“I would be one of the first people to use PrEP if it were available” and “Taking a daily HIV medicine would be a good way to protect myself from getting HIV”). Given the prevalence of HIV/AIDS conspiracy beliefs and medical mistrust among the population,[21-24] developing culturally-tailored community awareness campaigns and educational programs targeted to BMSM about the individual- and community-level benefits of PrEP may help change negative perceptions and facilitate adoption.

A significant proportion of participants reported high-risk sexual behaviors that placed them at-risk for HIV infection, but there was no association between sexual risk behaviors and PrEP adoption intention. Instead, a high PrEP adoption intention was indicated by participants reporting high-risk behaviors as well as those reporting low-risk behaviors. A similar finding was reported among BMSM attending a community event in the southeastern United States.[41] One possible explanation for the similar rates can be drawn from our earlier formative work where MSM indicated varied reasons for wanting to adopt PrEP. For example, some men wanted to use PrEP as an added layer of protection, in addition to using condoms, while others wanted to use PrEP in order to engage in condom-less sex and still feel protected from HIV.[25,34] The roll-out of PrEP as part of a combination HIV prevention strategy will be challenging as the reasons for adopting PrEP will vary among BMSM. For BMSM who adopt PrEP and then report risk compensation (i.e., condom-less sex while using PrEP), additional support services should be provided to address ongoing risk factors (e.g., substance abuse, mental health issues, transactional sex) contributing to high-risk behaviors; however, PrEP should continue to be available to these men as it may be their only prevention option.

The study findings are subject to several limitations. The cross-sectional design of the study precludes us from inferring causality. The study population consisted of a non-probability sample of BMSM, and therefore the findings may not be generalizable to BMSM in different regions of the country, or even in Los Angeles. Because PrEP delivery sites were not yet operational at the time of the present study, PrEP adoption intentions were assessed, which may not reflect actual future behavior.[33] To account for this limitation a conservative estimate of PrEP adoption intention was constructed. Another limitation is that sexual behavior was measured using an interviewer-administered survey, which may have

limited the accuracy of responses to sensitive and personal questions and may have underestimated actual risk behaviors.[42,43] In addition, because only a limited number of covariates were examined in the present study, future investigations should examine the relationship between social factors such as HIV stigma, HIV/AIDS conspiracy beliefs, and medical mistrust, and how these might relate to PrEP adoption among BMSM. Even with these limitations, the findings contribute to the literature on PrEP acceptability by offering a better understanding of the perceptions and interests in PrEP adoption among BMSM, which may prove useful in scaling up this biomedical intervention with the population.

Conclusion

The development of targeted educational and community awareness programs are needed to disseminate accurate information to BMSM about the benefits and availability of biomedical prevention tools such as PrEP. These efforts are needed in order to optimize the scale-up of these tools, prevent disparities in access, and contribute to reducing new HIV infections among BMSM.

Acknowledgements

The authors wish to thank the community-based organizations: In The Meantime, Los Angeles Gay and Lesbian Center, Friends Research, and Reach LA for their assistance in recruiting study participants. We also wish to thank research staff members Stanley Johnson, Demetria Villanueva, and Christopher Blades from the UCLA Vine Street Clinic for their assistance in implementing the study. We are grateful to the Black MSM of Los Angeles who participated in this study.

Funding

This work was supported by the California HIV/AIDS Research Program (grant #ID10-LA-029). The content of this article is solely the responsibility of the authors and does not necessarily reflect the views of the California HIV/AIDS Research Program.

Appendix 1: Complete list of PrEP-related attitude and belief items

- 1 Having PrEP available will make safer sex less important.
- 2 If my doctor suggested that I take PrEP to protect myself from getting HIV, I would take it.
- 3 Taking PrEP would mean you can have sex without using condoms.
- 4 If I was taking PrEP, I would be more likely to have sex without using a condom.
- 5 Taking a daily HIV medicine would be a good way to protect myself from getting HIV.
- 6 I would be very uncomfortable taking HIV medicines when I don't have HIV.
- 7 Not knowing if there are long-term side effects of taking a daily HIV medicine makes me very uncomfortable.
- 8 I would be very good at remembering to take a daily HIV pill to protect myself from getting HIV.
- 9 I would wait until other people were taking PrEP before I use it myself.
- 10 I would be one of the first people to use PrEP if it were available.
- 11 I would be more comfortable using PrEP if I knew just how it would affect my health.
- 12 If I was taking PrEP, I would feel more comfortable about having sex with someone who is HIV positive.
- 13 I would be very uncomfortable asking my doctor for PrEP pills to protect myself from getting HIV.
- 14 I would only take PrEP if it were available for free or covered by health insurance.
- 15 I would be concerned that people will think I have HIV if I am taking a HIV medicine.

- 16 I would be more willing to take PrEP if it had been tested previously with gay men.
- 17 I would be more willing to take PrEP if it had been tested previously with African-Americans.
- 18 I would be more willing to take PrEP if I didn't have to take it every day and could just take it a couple of days before having sex.
- 19 I would take PrEP even if it had minor side effects that went away after taking it for a few weeks.
- 20 If I was taking PrEP, I wouldn't worry about becoming infected with HIV when having sex with someone who is HIV-positive.
- 21 Taking an HIV medicine every day would make me more susceptible to getting infected with HIV.
- 22 If I was taking PrEP, I would be more likely to have anal sex without using a condom when I was the bottom or receptive partner.
- 23 If I was taking PrEP, I would be more likely to have anal sex without using a condom when I was the top or insertive partner.
- 24 If I was taking PrEP, I would most likely increase the number of sexual partners I have.

References

1. Centers for Disease Control and Prevention. [accessed September 2014] HIV Surveillance Report, 2011. 2013. <http://www.cdc.gov/hiv/topics/surveillance/resources/reports>
2. Centers for Disease Control and Prevention. [accessed January 2015] Estimated HIV incidence in the United States, 2007–2010. HIV Surveillance Supplemental Report 2012. 2012. http://www.cdc.gov/hiv/pdf/statistics_hssr_vol_17_no_4.pdf
3. MJ, Rotheram Borus; Swendeman, D.; Chovnick, G. The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annual review of clinical psychology. 2009; 5:143–67.
4. Peterson JL, Jones KT. HIV prevention for black men who have sex with men in the United States. Am J Public Health. 2009; 99(6):976–80. [PubMed: 19372510]
5. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med. 2012; 367(5):399–410. [PubMed: 22784037]
6. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587–99. [PubMed: 21091279]
7. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med. 2012; 367(5):423–34. [PubMed: 22784038]
8. Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Current opinion in HIV and AIDS. 2012; 7(2):99–105. [PubMed: 2227585]
9. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. The lancet. 2007; 369(9562):643–656.
10. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. The Lancet. 2007; 369(9562):657–666.
11. Kibengo FM, Ruzagira E, Katende D, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS ONE. 2013; 8(9):e74314. [PubMed: 24086333]
12. Q, Abdool Karim; SS, Abdool Karim; Frohlich, JA., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168–1174. [PubMed: 20643915]
13. Quinones-Mateu ME, Vanham G. HIV microbicides: where are we now? Current HIV research. 2012; 10(1):1–2. [PubMed: 22264039]
14. Paris RM, Kim JH, Robb ML, et al. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Review of Vaccines. 2010; 9(9):1055–1069. [PubMed: 20822348]

15. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. *Expert Review of Vaccines*. 2010; 9(9):997–1005. [PubMed: 20822342]
16. Food and Drug Administration. Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus. US Department of Health and Human Services, Food and Drug Administration; Silver Spring, MD: 2012. www.fda.gov/forconsumers/byaudience/forpatientadvocates/hivandaidsactivities/ucm312264.htm [accessed August 2014]
17. Centers for Disease Control and Prevention (CDC). [accessed August 2014] Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014 Clinical Practice Guideline. 2014. <http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf>
18. AIDS Vaccine Advocacy Coalition. [accessed September 2014] Ongoing and Planned PrEP Trials and Demonstration Projects, as of December 2013. <http://www.prepwatch.org/wp-content/uploads/2014/01/PrEP-Trials-and-Demo-Projects-December-2013.pdf>
19. Arnold EA, Rebchook GM, Kegeles SM. ‘Triply cursed’: racism, homophobia and HIV-related stigma are barriers to regular HIV testing, treatment adherence and disclosure among young Black gay men. *Culture, Health & Sexuality*. 2014; 16(6):710–722.
20. Bird JDP, Viosin DR. “You’re an open target to be abused”: A qualitative study of stigma and HIV self-disclosure among black men who have sex with men. *Am J Public Health*. 2013; 103(12): 2193–2199. [PubMed: 24134345]
21. Gamble VN. Under the shadow of Tuskegee: African Americans and health care. *Am J Public Health*. 1997; 87:1773–8. [PubMed: 9366634]
22. Thomas SB, Crouse-Quinn S. Public health then and now. The Tuskegee syphilis study, 1932-to-1972: Implications for HIV education and AIDS risk education programs in the Black community. *Am J Public Health*. 1991; 81:1498–1504. (1991). [PubMed: 1951814]
23. Bogart LM, Thorburn S. Are HIV/AIDS conspiracy beliefs a barrier to HIV prevention among African Americans. *J Acquir Immune Defic Syndr*. 2005; 38:213–218. [PubMed: 15671808]
24. Hutchinson AB, Begley EB, Sullivan P, et al. Conspiracy beliefs and trust in information about HIV/AIDS among minority men who have sex with men. *J Acquir Immune Defic Syndr*. 2007; 45:603–605. (2007).
25. Brooks RA, Kaplan RL, Lieber E, et al. Motivators, concerns, and barriers to adoption of pre-exposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. *AIDS Care*. 2011; 23(9):1136–45. [PubMed: 21476147]
26. Golub SA, Gamarel KE, Rendina HJ, et al. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. *AIDS Patient Care and STDs*. 2013; 27:248–254. [PubMed: 23565928]
27. Krakower DS, Mimiaga MJ, Rosenberger JG, et al. Limited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking Site. *PLOS ONE*. 2012; 7:e33119. [PubMed: 22470438]
28. Mimiaga MJ, Case P, Johnson CV, et al. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. *Journal of Acquired Immune Deficiency Syndromes*. 2009; 50:77–83. [PubMed: 19295337]
29. Smith DK, Toledo L, Smith DJ, et al. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). *AIDS Education and Prevention*. 2012; 24:408–421. [PubMed: 23016502]
30. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. *PLoS ONE*. 2007; 2:e875. [PubMed: 17878928]
31. Juusola JL, Brandeau ML, Owens DK, et al. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. *Annals of Internal Medicine*. 2012; 156:541–550. [PubMed: 22508731]
32. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. *Science translational medicine*. 2012; 4(151): 151ra125.

33. McEachan RRC, Conner M, Taylor NJ, et al. Prospective prediction of health related behaviours with the Theory of Planned Behaviour: a meta-analysis. *Health Psychology Review*. 2011; 5(2): 97–144.
34. Sanchez T, Finlayson T, Drake A, et al. Human immunodeficiency virus (HIV) risk, prevention, and testing behaviors – United States, National HIV Behavioral Surveillance System: men who have sex with men, November 2003 – April 2005. *MMWR Surveillance Summ*. 2006; 55:1–16.
35. Brooks RA, Landovitz RJ, Kaplan RL, et al. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. *AIDS Patient Care and STDs*. 2012; 2:87–94. [PubMed: 22149764]
36. Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies. *American Journal of Preventive Medicine*. 2013; 44(Suppl 2):S91–S98. [PubMed: 23253769]
37. Al Tayyib A, Thrun MW, Haukoos JS, et al. Knowledge of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men in Denver, Colorado. *AIDS and behavior*. 2014; 18(Suppl 3):340–7. [PubMed: 23824227]
38. Bauermeister JA, Meanley S, Pingel E, et al. PrEP awareness and perceived barriers among single young men who have sex with men. *Current HIV Research*. 2013; 11:520–527. [PubMed: 24476355]
39. Rucinski KB, Mensah NP, Sepkowitz KA, et al. Knowledge and use of pre-exposure prophylaxis among an online sample of young men who have sex with men in New York City. *AIDS and Behavior*. 2013; 17:2180–2184. [PubMed: 23479003]
40. Galindo GR, Walker JJ, Hazelton P, et al. Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. *Implementation Science*. 2012; 7(1):116–121. [PubMed: 23181780]
41. Eaton LA, Driffin D, Smith H, et al. Psychosocial factors related to willingness to use pre-exposure prophylaxis for HIV prevention among Black men who have sex with men attending a community event. *Sexual Health*. 2014; 11(3):244–51. [PubMed: 25001553]
42. Des Jarlais DC, Paone D, Milliken J, et al. Audiocomputer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. *Lancet*. 1999; 353:1657–1661. [PubMed: 10335785]
43. Turner CF, Ku L, Rogers SM, et al. Adolescent sexual behavior, drug use and violence: increased reporting with computer survey technology. *Science*. 1998; 280(5365):867–73. [PubMed: 9572724]

Table 1

Demographics and sexual risk behaviors by PrEP adoption intention (n=224).

Characteristics/Sexual Behaviors	Total Population	PrEP adoption intention	
	N (%)	High N (%)	Low N (%)
Age (M= 33.5, SD=11.8)			
18-29	114 (50.9)	71 (53.0)	43 (47.8)
30+	110 (49.1)	63 (47.0)	47 (52.2)
Sexual identity			
Gay	125 (55.8)	81 (60.4)	44 (48.9)
Bisexual	90 (40.2)	49 (36.6)	41 (45.6)
Other	9 (4.0)	4 (3.0)	5 (5.6)
Education completed			
11 th grade	31 (13.8)	20 (14.9)	11 (12.2)
High school	73 (32.6)	46 (34.3)	27 (30.0)
Some college	95 (42.4)	55 (41.0)	40 (44.4)
College degree	8 (11.1)	13 (9.7)	12 (13.3)
Employment status			
Employed FT/PT	99 (44.2)	56 (41.8)	43 (47.8)
Unemployed/disabled	125 (55.8)	78 (58.2)	47 (52.2)
Annual income			
\$19,999	149 (66.5)	94 (70.1)	55 (61.1)
\$20,000	75 (33.5)	40 (29.9)	35 (38.9)
Number of male sex partners past 6 mos.			
2 male partners	107 (50.7)	68 (52.3)	39 (48.1)
3 male partners	104 (49.3)	62 (47.7)	42 (51.9)
Receptive anal (RA) sex past 6 mos.			
Yes	118 (52.9)	73 (54.5)	45 (50.6)
No	105 (47.1)	61 (45.5)	44 (49.4)
Condoms used for RA sex past 6 mos.			
Consistent condom use	63 (51.6)	39 (51.3)	24 (52.2)
Inconsistent condom use	59 (48.4)	37 (48.7)	22 (47.8)
Last RA sex encounter condoms used			
Yes	76 (62.8)	51 (68.0)	25 (54.3)
No	45 (37.2)	24 (32.0)	21 (45.7)
Insertive anal (IA) sex past 6 mos.			
Yes	188 (84.3)	114 (85.1)	74 (83.1)
No	35 (15.7)	20 (14.9)	15 (16.9)
Condoms used for IA sex past 6 mos.			
Consistent condom use	89 (47.3)	58 (50.9)	31 (41.9)
Inconsistent condom use	99 (52.7)	56 (49.1)	43 (58.1)
Last IA sex encounter condoms used			

Characteristics/Sexual Behaviors	Total Population	PrEP adoption intention	
	N (%)	<u>High</u> N (%)	<u>Low</u> N (%)
Yes	116 (61.7)	76 (66.7)	40 (54.1)
No	72 (38.3)	38 (33.3)	34 (45.9)

Table 2

Prep-related attitudes and beliefs by PrEP adoption intention (n = 224).

	Total Population	PrEP adoption intention	
		High	Low
Statements	N (%)	N (%)	N (%)
I would be very uncomfortable taking HIV medicines when I don't have HIV			
Disagree/strongly disagree	145 (66.8)	104 (80.0)	41 (47.1)*
Agree/strongly agree	72 (33.2)	26 (20.0)	46 (52.9)
Not knowing if there are long-term side effects of taking a daily HIV medicine makes me very uncomfortable			
Disagree/strongly disagree	80 (36.0)	59 (44.4)	21 (23.6)**
Agree/strongly agree	142 (64.0)	74 (55.6)	68 (76.4)
I would wait until other people were taking PrEP before I use it myself			
Disagree/strongly disagree	137 (61.7)	95 (72.0)	42 (46.7)***
Agree/strongly agree	85 (38.3)	37 (28.0)	48 (53.3)
I would be one of the first people to use PrEP if it were available			
Disagree/strongly disagree	95 (43.3)	34 (25.8)	61 (69.3)***
Agree/strongly agree	125 (56.8)	98 (74.2)	27 (30.7)
I would be very uncomfortable asking my doctor for PrEP pills to protect myself from getting HIV			
Disagree/strongly disagree	197 (87.9)	124 (92.5)	73 (81.1)**
Agree/strongly agree	27 (12.1)	10 (7.5)	17 (18.9)
If I was taking PrEP, I would feel more comfortable about having sex with someone who is HIV-positive			
Disagree/strongly disagree	146 (66.7)	81 (61.4)	65 (74.7)*
Agree/strongly agree	73 (33.3)	51 (38.6)	22 (25.3)
I would be concerned that people will think I have HIV if I am taking an HIV medicine			
Disagree/strongly disagree	143 (64.4)	93 (70.5)	50 (55.6)*
Agree/strongly agree	79 (35.6)	39 (29.5)	40 (44.4)
If I was taking PrEP, I wouldn't worry about becoming infected with HIV when having sex with someone who is HIV-positive			
Disagree/strongly disagree	174 (78.7)	96 (72.2)	78 (88.6)**
Agree/strongly agree	47 (21.3)	37 (27.8)	10 (11.4)
Taking a daily HIV medicine would be a good way to protect myself from getting HIV			
Disagree/strongly disagree	20 (9.2)	1 (0.8)	19 (22.4)***
Agree/strongly agree	197 (90.8)	131 (99.2)	66 (77.6)

* p < .05

** p .01

p .001

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

PrEP and PEP awareness and prior use by PrEP adoption intention (n=224).

Awareness and Prior Use	Total Population	PrEP adoption intention	
	N (%)	High N (%)	Low N (%)
PrEP awareness			
Yes	74 (33.0)	44 (32.8)	30 (33.3)
No	150 (67.0)	90 (67.2)	60 (66.7)
Prior PrEP use			
Yes	0 (0.0)	--	--
No	224 (100.0)	134 (59.8)	90 (40.2)
PEP awareness			
Yes	81 (36.2)	48 (35.8)	33 (36.7)
No	143 (63.8)	86 (64.2)	57 (63.3)
Prior PEP use			
Yes	7 (3.1)	5 (3.8)	2 (2.2)
No	216 (96.4)	128 (96.2)	88 (97.8)

Table 4

Multivariate logistic regression analysis for PrEP adoption intention (n = 224).

Variable	Adjusted Odds Ratio (95% CI)
Age	
18-29	2.29 (1.06-4.93) *
30+	1.00
I would be very uncomfortable taking HIV medicines when I don't have HIV	
Disagree/strongly disagree	1.00
Agree/strongly agree	0.39 (0.16-0.91) *
Not knowing if there are long-term side effects of taking a daily HIV medicine makes me very uncomfortable	
Disagree/strongly disagree	1.00
Agree/strongly agree	0.36 (0.14-0.88) *
I would be one of the first people to use PrEP if it were available	
Disagree/strongly disagree	1.00
Agree/strongly agree	4.13 (1.74-9.81) **
Taking a daily HIV medicine would be a good way to protect myself from getting HIV	
Disagree/strongly disagree	1.00
Agree/strongly agree	2.26 (1.6-3.17) **

1.00 = referent group

*
p < .05**
p .001